Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.74 |
| ▸ | NPC1 | O15118 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.62 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | HPGDS | O60760 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1858111 | 0.88 | RAB9A (0.78) | RAB9AKMT2ANPC1ALDH1A1MEN1 | |
| SCHEMBL28564828 | 0.85 | RAB9A (0.74) | RAB9AKMT2ANPC1ALDH1A1MEN1 | |
| SCHEMBL4739925 | 0.85 | RAB9A (0.73) | RAB9AKMT2ANPC1ALDH1A1MEN1 | |
| SCHEMBL11887623 | 0.81 | MEN1 (1.00) | RAB9AKMT2ANPC1ALDH1A1MEN1 | |
| SCHEMBL1862847 | 0.81 | RAB9A (0.68) | RAB9AKMT2ANPC1ALDH1A1MEN1 | |
| SCHEMBL12857660 | 0.80 | RAB9A (1.00) | RAB9AKMT2ANPC1ALDH1A1MEN1 | |
| SCHEMBL1859778 | 0.80 | RAB9A (0.70) | RAB9AKMT2ANPC1ALDH1A1MAPT | |
| SCHEMBL1867069 | 0.80 | RAB9A (0.73) | RAB9AKMT2ANPC1ALDH1A1MEN1 | |
| SCHEMBL400890 | 0.79 | RAB9A (0.77) | RAB9AKMT2ANPC1ALDH1A1MEN1 | |
| SCHEMBL7060779 | 0.79 | RAB9A (0.66) | RAB9AKMT2ANPC1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030060473-A1 | Piperazine compounds as inhibitors of MMP or TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| US-6489324-B2 | TREATING STROKE, ARHTRITIS, CANCER, TISSUE ULCERATION, DECUBITIS ULCER, RESTENOSIS, PERIODONTAL DISEASE, EPIDERMOLYSIS BULLOSA, SCLERITIS, PSORIASIS, AIDS, SEPSIS, AND SEPTIC SHOCK. | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| US-6333324-B1 | FOR THERAPY AND PROPHYLAXIS OF MATRIX METALLOPROTEINASES (MMP) OR TUMOR NECROSIS FACTOR .ALPHA. (TNF.ALPHA.), MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| EP-0948489-A1 | PIPERAZINE COMPOUNDS AS INHIBITORS OF MMP OR TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998027069-A1 | PIPERAZINE COMPOUNDS AS INHIBITORS OF MMP OR TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-25 | — | — | WO | disclosed |
| EP-0361645-A2 | Organic hydrazine derivatives for pharmaceutical use | ROHM AND HAAS COMPANY (US) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060473-A1 | Piperazine compounds as inhibitors of MMP or TNF | MMP2, MMP1, TNF | RAB9A 3610/4885KMT2A 1432/4885NPC1 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.